Sun Pharma surges on acquiring three anti-inflammatory brands from Aksigen Hospital Care
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Sun Pharmaceutical Industries is currently trading at Rs. 1048.55, up by 4.95 points or 0.47% from its previous closing of Rs. 1043.60 on the BSE.
The scrip opened at Rs. 1035.00 and has touched a high and low of Rs. 1071.90 and Rs. 1035.00 respectively. So far 56152 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,071.90 on 30-Jan-2023 and a 52 week low of Rs. 789.75 on 17-Jun-2022.
Last one week high and low of the scrip stood at Rs. 1,071.90 and Rs. 1028.05 respectively. The current market cap of the company is Rs. 251258.36 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.01% and 9.51% respectively.
Sun Pharmaceutical Industries has acquired three anti-inflammatory brands from Mumbai-based Aksigen Hospital Care. The company has acquired Disperzyme, Disperzyme-CD and Phlogam as part of the deal.
All the brands are approved by the Drugs Controller General of India (DCGI) for post-operative inflammation in patients undergoing minor surgery and dental procedures. Disperzyme and Phlogam are the first enzyme-bioflavonoid combinations of Trypsin, Bromelain and Rutoside to complete a clinical study in India and get DCGI approval.
